Provectus Biopharmaceuticals Inc.’ Poster Presentation On PV-10 Clinical Data From Phase 1 Study For Cancers Of The Liver Scheduled For Thursday, July 2, 2015 At 17th World Congress On Gastrointestinal Cancer

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Biopharmaceuticals, Inc. (NYSE MKT:PVCT,, a clinical-stage oncology and dermatology biopharmaceutical company (“Provectus” or the “Company”), announced today that the abstract titled, "Phase 1 Study of PV-10 for Chemoablation of Hepatocellular Cancer and Cancer Metastatic to the Liver," to be presented at the European Society for Medical Oncology’s 17th World Congress on Gastrointestinal Cancer, is scheduled for Thursday, July 2, 2015 from 10:30 to 11:00 a.m. and 4:55 to 5:25 p.m. local time. Sanjiv S. Agarwala, MD, of St. Luke's University Hospital and Health Network, Bethlehem, PA, will be the presenter.

Help employers find you! Check out all the jobs and post your resume.

Back to news